Abstract
Heart failure (HF) is currently one of the major health problems in Poland and in other European countries. Despite the progress that has been made in the treatment of HF, mortality and the incidence of re-hospitalization for HF are still very high. One of the reasons is the lack of proper heart failure treatment optimization. Among the currently studied new biomarkers of heart failure, one of the special interest is circulating receptor for IL-33 (sST2). It has been shown that IL-33 plays cardioprotective role. Its molecular mechanisms of action are based mainly on the activation of the transmembrane form of ST2 receptor (ST2L). Availability of IL-33 for ST2L is limited by binding to the soluble fraction of the ST2 (sST2) — called a „decoy receptor”. The presence of elevated levels of sST2 in the population of patients with heart failure is associated with more severe left ventricular remodeling, impaired diastolic function and right ventricle function. Patients with both HF and high and/or rising levels sST2 are at high risk of adverse cardiovascular events. The standard treatment for heart failure leads to reduction in sST2 concentration. Among the drugs used in the heart failure treatment, two with the largest impact on reducing concentration of sST2 are beta-blockers in high doses, and aldosterone.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
